Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology - WNEM TV 5

Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Analysts Review

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, May 20, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Puma Biotechnology, Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2665-100free.

--
Gilead Sciences, Inc. Analyst Notes
On May 10, 2014, Gilead Sciences, Inc. (Gilead) announced results from HARMONY, a randomized, double-blind, placebo-controlled Phase 2 study that evaluates the effect of ranolazine and low-dose dronedarone, each given alone and in combination, on atrial fibrillation burden (AFB) in patients with paroxysmal atrial fibrillation (AF). The Company informed that results showed that the combination of ranolazine and low-dose dronedarone provided greater reductions in AFB from baseline than either therapy used alone. "HARMONY suggests that a new therapeutic approach of combining ranolazine and low-dose dronedarone is more effective than either therapy alone in lowering AF burden. Pending larger Phase 3 evaluation, a combination of ranolazine and low-dose dronedarone has the potential to help address a significant and growing unmet need for additional treatment options for people living with this serious disease," said Peter R. Kowey, MD, William Wikoff Smith Chair in Cardiovascular Research at Lankenau Medical Center and Professor of Medicine and Clinical Pharmacology at Jefferson Medical College, Thomas Jefferson University. The full analyst notes on Gilead are available to download free of charge at:

http://www.analystsreview.com/2665-GILD-20May2014.pdf

--
Questcor Pharmaceuticals, Inc. Analyst Notes
On May 14, 2014, Questcor Pharmaceuticals, Inc. (Questcor) announced that it has entered into a development collaboration agreement with an undisclosed privately held European company to develop novel melanocortin peptides. The Company informed that the collaboration includes an option to acquire the technology during clinical development. "We are particularly excited that this collaboration allows us to build on our success by investing in the development of the next generation of melanocortin therapeutics," said Steve Cartt, COO of Questcor. Cartt added, "This effort has the potential to more effectively address certain diseases where the broader melanocortin pharmacological profiles of both Acthar and Synacthen are less desirable, including new indications for which neither product is presently utilized." The Company informed that terms of this collaboration have enabled it to secure an exclusive worldwide license to the peptides and technology. The full analyst notes on Questcor are available to download free of charge at:

http://www.analystsreview.com/2665-QCOR-20May2014.pdf

--
Vertex Pharmaceuticals Incorporated Analyst Notes
On May 7, 2014, Vertex Pharmaceuticals Incorporated (Vertex) announced that William Young has joined the Company's Board of Directors as an independent director, taking the board size to 10 members. The Company informed that Young was elected to the class of directors whose term expires in 2017. "Mr. Young is a recognized leader within the biotech industry and brings a wealth of scientific and operational experience to our Board," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and CEO of Vertex. "Importantly, Mr. Young has been part of multiple life sciences companies at times of rapid growth and transition. His insights will be invaluable to Vertex as we continue to focus our business on advancing transformative medicines for people with cystic fibrosis." The full analyst notes on Vertex are available to download free of charge at:

http://www.analystsreview.com/2665-VRTX-20May2014.pdf

--
ARIAD Pharmaceuticals, Inc. Analyst Notes
On May 14, 2014, ARIAD Pharmaceuticals, Inc. (ARIAD) announced that clinical data on Iclusig (ponatinib) and AP26113 will be presented at the Annual Meeting of the American Society of Clinical Oncology, which will be held from May 30 to June 3, 2014 in Chicago. The Company informed that a breakfast meeting featuring key investigators who will review clinical data from Iclusig and AP26113 will be webcast live on June 2, 2014 at 7:30-8:30 a.m. CT in Chicago Hilton, Marquette Room. The full analyst notes on ARIAD are available to download free of charge at:

http://www.analystsreview.com/2665-ARIA-20May2014.pdf

--
Puma Biotechnology, Inc. Analyst Notes
On May 12, 2014, Puma Biotechnology, Inc. (Puma Biotechnology) reported Q1 2014 financial results. Q1 2014 net loss was $19.8 million, or $0.67 loss per common share, compared to a net loss of $11.8 million, or $0.41 loss per common share, in Q1 2013. As of March 31, 2014, Puma Biotechnology had cash and cash equivalents of $163.4 million and marketable securities of $32.7 million, compared to cash and cash equivalents of $43.0 million and marketable securities of $40.9 million at December 31, 2013. "During the first quarter of 2014 we achieved several important milestones, including the continued advancement of our Phase II and Phase III clinical trials for PB272," said Alan H. Auerbach, Chairman, CEO and President of Puma Biotechnology. "We look forward to continuing to advance the clinical development of PB272 during the remainder of 2014." The full analyst notes on Puma Biotechnology are available to download free of charge at:

http://www.analystsreview.com/2665-PBYI-20May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
WNEM
Powered by WorldNow CNN
All content © 2014, WNEM; Saginaw, MI. (A Meredith Corporation Station) and WorldNow. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.